These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 14578761

  • 1. C2 monitoring in maintenance renal transplant recipients: is it worthwhile?
    Midtvedt K, Fauchald P, Bergan S, Høieggen A, Hallan S, Svarstad E, Bergrem H, Eriksen BO, Pfeffer PF, Dalen I, Leivestad T.
    Transplantation; 2003 Oct 27; 76(8):1236-8. PubMed ID: 14578761
    [Abstract] [Full Text] [Related]

  • 2. Early cyclosporine C0 and C2 monitoring in de novo kidney transplant patients: a prospective randomized single-center pilot study.
    Kyllönen LE, Salmela KT.
    Transplantation; 2006 Apr 15; 81(7):1010-5. PubMed ID: 16612277
    [Abstract] [Full Text] [Related]

  • 3. Clinical outcomes and C2 cyclosporin monitoring in maintenance renal transplant recipients: 1 year follow-up study.
    Marcén R, Villafruela JJ, Pascual J, Teruel JL, Ocaña J, Tenorio MT, Burgos FJ, Ortuño J.
    Nephrol Dial Transplant; 2005 Apr 15; 20(4):803-10. PubMed ID: 15687111
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cyclosporine concentrations 2 hours post-dose determined using 3 different methods and trough level in pediatric renal transplantation.
    Rodríguez E, Delucchi MA, Cano F, Valdebenito S, Castillo MC, Villegas R.
    Transplant Proc; 2005 Oct 15; 37(8):3354-7. PubMed ID: 16298594
    [Abstract] [Full Text] [Related]

  • 5. Evolution of the absorption profile of cyclosporine A in renal transplant recipients: a longitudinal study of the de novo and maintenance phases.
    Büchler M, Chadban S, Cole E, Midtvedt K, Thervet E, Prestele H, Keown P.
    Nephrol Dial Transplant; 2006 Jan 15; 21(1):197-202. PubMed ID: 16204301
    [Abstract] [Full Text] [Related]

  • 6. Cyclosporine dose reduction in stable renal transplant patients with high C2 level: simplified method of single C2 measurement and individualization of C0 target.
    Higgins RM, Kanji H, Hernon M, Harrison P, Lam FT, Kashi SH.
    Transpl Int; 2005 Jul 15; 18(7):806-10. PubMed ID: 15948859
    [Abstract] [Full Text] [Related]

  • 7. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
    Davies RA, Veinot JP, Williams K, Haddad H, Baker A, Donaldson J, Pugliese C, Struthers C, Masters RG, Hendry PJ, Mesana T.
    Transplant Proc; 2007 Dec 15; 39(10):3334-9. PubMed ID: 18089382
    [Abstract] [Full Text] [Related]

  • 8. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
    Hmiel SP, Canter C, Shepherd R, Lassa-Claxton S, Nadler M.
    Pediatr Transplant; 2007 Aug 15; 11(5):524-9. PubMed ID: 17631021
    [Abstract] [Full Text] [Related]

  • 9. A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens.
    Dösch AO, Ehlermann P, Koch A, Remppis A, Katus HA, Dengler TJ.
    Clin Ther; 2006 Jun 15; 28(6):893-905. PubMed ID: 16860172
    [Abstract] [Full Text] [Related]

  • 10. C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients.
    Caforio AL, Tona F, Piaserico S, Gambino A, Feltrin G, Fortina AB, Angelini A, Alaibac M, Bontorin M, Calzolari D, Peserico A, Thiene G, Iliceto S, Gerosa G.
    Transpl Int; 2005 Jan 15; 18(1):116-24. PubMed ID: 15612993
    [Abstract] [Full Text] [Related]

  • 11. Three-years experience with Neoral C2 monitoring adjusted to a target range of 500-600 ng/ml in long-term renal transplant recipients receiving dual immunosuppressive therapy.
    Carstens J.
    Scand J Urol Nephrol; 2008 Jan 15; 42(3):286-92. PubMed ID: 18432535
    [Abstract] [Full Text] [Related]

  • 12. Experience with cyclosporine: approaching the therapeutic window for C2 levels in maintenance kidney transplant recipients.
    Di Paolo S, Teutonico A, Infante B, Stallone G, Schena A, Grandaliano G, Battaglia M, Di Tonno P, Schena FP.
    Transplant Proc; 2004 Mar 15; 36(2 Suppl):434S-436S. PubMed ID: 15041381
    [Abstract] [Full Text] [Related]

  • 13. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function.
    Domínguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R.
    Transplant Proc; 2005 Apr 15; 37(3):1583-5. PubMed ID: 15866680
    [Abstract] [Full Text] [Related]

  • 14. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
    Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F, Cillo U, Clavien PA, Klintmalm G, Otto G, Pollard S, McCormick PA.
    Liver Transpl; 2006 Oct 15; 12(10):1464-72. PubMed ID: 17004259
    [Abstract] [Full Text] [Related]

  • 15. Advantages of C2 monitoring to avoid acute rejection in pediatric heart transplant recipients.
    Schubert S, Abdul-Khaliq H, Lehmkuhl HB, Hübler M, Abd El Rahman MY, Miera O, Ewert P, Weng Y, Wei H, Krüdewagen B, Hetzer R, Berger F.
    J Heart Lung Transplant; 2006 Jun 15; 25(6):619-25. PubMed ID: 16730566
    [Abstract] [Full Text] [Related]

  • 16. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
    Akhlaghi F, Gonzalez L, Trull AK.
    J Heart Lung Transplant; 2005 Dec 15; 24(12):2120-8. PubMed ID: 16364860
    [Abstract] [Full Text] [Related]

  • 17. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation.
    Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, Khasati N, Keevil B, Yonan N.
    J Heart Lung Transplant; 2006 May 15; 25(5):564-8. PubMed ID: 16678036
    [Abstract] [Full Text] [Related]

  • 18. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
    Bunnag S, Vareesangthip K, Ong-ajyooth L.
    J Med Assoc Thai; 2006 Aug 15; 89 Suppl 2():S228-34. PubMed ID: 17044476
    [Abstract] [Full Text] [Related]

  • 19. A survey to determine the blood concentration of cyclosporine 2 hours postdose in stable renal transplant patients.
    Jorga A, Holt DW, Yaqoob M, Whittaker C, Johnston A.
    Transplant Proc; 2004 Dec 15; 36(10):3239-41. PubMed ID: 15686737
    [Abstract] [Full Text] [Related]

  • 20. Analysis of liver function in renal transplant recipients undergoing C2-monitoring for cyclosporine.
    Hecking M, Kainz A, Schillinger M, Posch C, Birsan T, Rasoul-Rockenschaub S, Böhmig GA, Schmaldienst S, Watschinger B, Hörl WH, Mühlbacher F, Säemann MD.
    Transpl Int; 2008 Mar 15; 21(3):223-33. PubMed ID: 17903183
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.